as the Ki-67 proliferation index (Ki-67 PI). However, the results of earlier studies investigating the relationship between the Ki-67 PI, local control (LC) and survival after primary RT in laryngeal squamous cell cancer (LSCC) are not unambiguous, as shown in Table 1 . [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Possible explanations for these differences are variations in patient group factors, immunostaining and scoring-related factors. [15] [16] [17] The aim of this study was to assess the value of Ki-67 PI in predicting LC and disease-specific survival (DSS) after primary RT in a well-defined consecutive series of patients with early-stage (T1-T2) LSCC. By using standardised and automated immunohistochemistry along with digital image analysis (DIA) to assess the Ki-67 PI, we reduced staining and scoring variability.
| PATIENTS AND ME THODS

| Patients
Patients treated for LSCC at our institution are included in a database by the Netherlands Cancer Registry (NCR) by using the results of the nationwide network and registry of histo-and cytopathology in the Netherlands (PALGA). Retrospectively, data from the hospital consisting of date of birth, sex, tumour site, TNM status, tumour classification and therapy modality are collected. 18, 19 From this database, a consecutive series of patients was included in the current study 
| Ethical considerations
According to the Central Committee on Research involving Human Subjects (CCMO), this type of study did not require approval from an ethics committee in the Netherlands. This study was approved by the Privacy Review Board of the NCR by following "The Code of Conduct for the Use of Data in Health Research" of the CCMO. 23 
| Treatment
All patients were treated by a multidisciplinary head & neck team.
Patients received primary RT with curative intent using 6MV linear accelerator equipment as previously described. [20] [21] [22] In short, T1 tumours received 2 Gy fractions five times weekly with a total dose of 66 Gy. T2 tumours were treated with six fractions weekly to a total dose of 70 Gy.
In case of lymph node metastasis, a total dose of 46 Gy was electively delivered to the primary planning target volume together with an additional boost of 70 Gy to the primary tumour and pathologic lymph nodes. From the year 2000 onwards, planning of field arrangements was performed by using contrast-enhanced computed tomography (CT). Before 2000, this was calculated by direct simulation (Figure 1 ).
| Follow-up
All patients had standardised follow-up after completing RT in accordance with the Dutch Working Party on Head and Neck Tumours (NWHHT) guidelines. 24 For the first 2 years, the otorhinolaryngology and radiotherapy department alternately performed physical examination with laryngoscopy every 3 months. After 2 years, this was alternately performed every 6 months up till 5 years after completing radiation treatment. Patients were discharged from followup after 5 years if no evidence of disease was found.
| Immunohistochemistry
All tumour material was formalin-fixed and paraffin-embedded. 
Key points
• Ambiguous results regarding the predictive value of the Ki-67 proliferation index regarding local control and survival after primary radiotherapy have been reported in early-stage laryngeal squamous cell cancer.
• Small study size, heterogeneous inclusion, variations in immunostaining and cut-off values are factors attributing to these contradictory results.
• We used a well-defined series of T1-T2 laryngeal tumours treated with radiotherapy, standardised automatic immunostaining and automatic digital scoring.
• Standardised and automated staining minimises variable staining intensity and improves reproducibility.
Automated digital scoring eliminates interobserver variability.
• The Ki-67 proliferation index was not a predictor for local control or disease-specific survival and therefore should not be incorporated in treatment-related decision-making for early-stage laryngeal squamous cell cancer.
| Evaluation of immunohistochemical staining
A whole tumour slide was analysed in order to reduce sampling error. All glass slides digitized using the Hamamatsu Nanozoomer Images were processed in one batch automatically for identification and calculation of nuclear staining. Twenty random cases were selected and manually counted by the head & neck pathologist to validate the image analysis algorithm. All slides contained at least 500 countable cells (median 7308, range 509-121.847).
| Definitions
LC was defined as local tumour recurrence at the primary tumour site within 2 years after RT and was calculated from the date of diagnosis until the date of recurrence. After this period of 2 years, any local recurrence was defined as a second primary tumour. DSS was defined as the date of diagnosis until the date of death by disease or last date of follow-up within 5 years.
In the analyses, Ki-67 PI was considered both as a continuous and a dichotomous variable. For dichotimisation, the cut-off value for high vs low Ki-67 PI was set to 50%, which was defined by the median Ki-67 expression in our cohort. In addition, we also tried to compare our data with previously published studies, which used cutoff values of 10% and 20%. [7] [8] [9] 12, 13 Alcohol use was defined as drinking one or more units per day either in the past or at date of diagnosis. The same was applied for tobacco use with smoking one or more cigarettes or sigars per day.
| Statistical analysis
Patients were dichotomised based on their Ki-67 PI, and for correlations between patient and tumour characteristics, univariate logistic 
| RE SULTS
Patient and tumour characteristics are described in Table 2 . The majority of tumours were of glottic origin, had a T2 status, did not have lymph node metastasis and were moderately differentiated. Most (Figure 1 ). Median Ki-67 PI was 49% (range 4%-89%). As this approached the 50% cut-off used in other studies, we also used a 50% cut-off between high and low Ki-67 PI for comparability. Using a 10% and 20% cut-off, a high Ki-67 PI was found in 207 cases (99.5%) and 199 cases (95.7%), respectively. As the low Ki-67 PI group was too small for both cut-offs (one and nine cases respectively), no further statistical analyses were performed using these cut-offs.
In the univariate regression analysis using a 50% cut-off for the Ki-67 PI, no significant associations between clinicopathological variables and Ki-67 PI were found (Table 3) . When treated as a continuous variable, no significant associations between Ki-67 PI and the evaluated variables were found (Table 3) .
A significant negative association between LC and poor tumour were found ( Figure S1A , Table 4 ).
In univariate and stepwise multivariate Cox regression analysis, a significant negative association was found between lymph node positivity and DSS (HR 3.16, 95% CI 1.16-8.64; P = .03). No associations were found between Ki-67 PI and DSS (HR 0.98; 95% CI 0.57-1.66; P = .97) or KI67 PI as a continuous variable and DSS (HR 0.62; 95% CI 0.05-8.28; P = .72) ( Figure S1B , Table 5 ). From the eleven previously conducted studies, 15 (sub)analyses were reported or could be calculated using the data and cut-off values provided in the papers (Table 1 ). Of those, nine did not find a significant association between Ki-67 PI and LC after RT. [6] [7] [8] [9] [10] [11] 13, 14 Two subgroup analyses in one study showed a negative association between high Ki-67 and LC in both a cohort treated with accelerated RT (ART) and in a combined cohort treated with either ART or conventional RT (HR 2.66; 95% CI 1.17-6.08 and HR 5.11;
| D ISCUSS I ON
95% CI 1.53-17.06 respectively). 5 Nichols et al found a worse local, regional or distant control in patients with high Ki-67 tumours. 12 Three studies showed a significant positive association between high Ki-67 and LC after RT using continuous values, and one study showed a positive association using a 50% cut-off (no HR or 95% CI was given or could be calculated). 4, 9, 10 However, selection bias may have influenced the outcome of these studies as in one of the studies 36 patients were randomly selected from a larger cohort of 128 patients, 9 another study included only 24 patients with a glottic carcinoma involving the anterior commissure in a 10-year period. From five subanalyses of the four studies that assessed the association between Ki-67 and survival, none found a difference in OS, 5, 8 DSS 5,13 or survival (not otherwise specified). 10 In one paper, worse regional control and metastasis-free survival were reported. 13 A confounder for this result might be the inclusion of advanced LSCC, which has a much higher tendency to metastasise (regionally). Our study only consisted of early-stage LSCC. The role of Ki-67 in advanced tumours could be the subject of a follow-up study.
Consensus on Ki-67 staining protocols, Ki-67 antibodies and scoring methods is still lacking. The published cut-offs for high vs low Ki-67 PI varied between 10%, 20% and 50%, along with continuous values. We believe tumour markers without pre-set cutoff value (ie continuous values) are deemed less fit as diagnostic biomarker for decision-making regarding different therapeutic modalities.
Various definitions regarding LC after radiotherapy make it even more difficult to compare study results. A global definition for LC is needed in order to have better comparability across studies. Despite this lack of consensus, this seems not to be explanatory for the different outcomes.
In our cohort, we found a relatively high Ki-67 PI compared with other studies. One of the explanations might be that we used marked HE slides to accurately determine and select neoplastic re- 26 A moderate reproducibility across the laboratories was found when they used their own scoring methodology on sections stained in a central laboratory. This reproducibility declined even further when both staining and scoring were done locally.
By using a standardised and automated staining platform with a pre-diluted antibody by the supplier, we minimised this problem and improved reproducibility, enabling future interlaboratory comparison. 
| CON CLUS ION
